Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar through glucagon suppression.

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

What’s behind Gen Z’s skepticism about Ozempic and Wegovy

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight loss. Concerns focused on safety, social stigma, and a preference for lifestyle changes like diet and exercise.

24 Apr 2025

Body image concerns drive interest in GLP-1 weight loss drugs, study finds

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with interest in GLP-1 medications for weight loss. Conversely, body appreciation appears to protect against this interest, especially in the face of potential side effects.

23 Apr 2025

Monell study offers renewed hope for people living with Bardet-Biedl Syndrome

A Monell Chemical Senses Center study published this week in the Journal of Clinical Investigation offers renewed hope for individuals living with Bardet-Biedl Syndrome (BBS), a rare genetic disorder characterized by early-onset obesity, compulsive eating, and cognitive impairments.

18 Apr 2025

Study: Women show greater awareness of obesity drugs than men

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that women are much more aware of knowledgeable about the obesity drugs GLP-1/GIP receptor agonists (that include semaglutide and tirzepatide).

17 Apr 2025

GLP1 agonists linked to depression risk in new genetic study

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists-widely used in blockbuster drugs like Ozempic-and the risk of depression and suicidal ideation (SI).

17 Apr 2025

New Canadian guidelines offer comprehensive approach to managing pediatric obesity

Researchers provide evidence-based recommendations to manage pediatric obesity.

17 Apr 2025

Comparing single cell RNA methods to improve gastrointestinal cancer research

Research on gastrointestinal diseases, especially cancer, has mainly looked at the epithelial cells, which line the surfaces of organs, are important for various functions, and are believed to be the cells that go awry to cause these diseases.

16 Apr 2025

New findings highlight a shifting landscape for weight loss and glucose managing medications

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.

15 Apr 2025

GLP-1 agonists may reshape the gut microbiome

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory benefits for diabetes management.

11 Apr 2025

Study shows minimal lean muscle mass loss with GLP-1 and GLP-1/GIP therapy for weight loss

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for weight loss experienced minimal lean muscle mass loss as they lost weight across 6 months of treatment.

9 Apr 2025

Semaglutide linked to higher risk of vision problems, FDA data analysis shows

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher reporting rate of vision impairment. The findings call for further study into the ocular risks of this widely prescribed diabetes and weight loss drug.

8 Apr 2025

American College of Physicians announces $260,000 in grants to advance equitable obesity care

Today, the American College of Physicians (ACP) announced that it has awarded a total of $260,000 in grants to support regional programs that address equity challenges in obesity care.

3 Apr 2025

Experts develop new guidelines for the treatment of schizophrenia

New guidelines have been developed for the treatment of schizophrenia after a collaboration of international experts from 30 countries.

2 Apr 2025

Rare sugars curb appetite and mimic diabetes drugs in mice

Rare sugars like D-allulose, D-tagatose, and D-sorbose significantly boosted GLP-1 secretion and suppressed food intake in mice. D-allose also reduced food intake through a unique, GLP-1-independent pathway.

1 Apr 2025

UVA Health experts highlight a growing array of treatment options for type 2 diabetes

Nearly 40% of patients diagnosed with type 2 diabetes imperil their health by stopping their medication within the first year, UVA Health diabetes experts note in a new paper highlighting a growing array of treatment options.

1 Apr 2025

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

1 Apr 2025

New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even alcohol cravings.

31 Mar 2025

Why sucralose could make you hungrier instead of helping you lose weight

Sucralose increases hypothalamic activity linked to hunger more than sugar or water, especially in women and people with obesity.

30 Mar 2025

Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first-of-its kind trial to evaluate the use of a GLP-1 agonist to manage PAD.

29 Mar 2025

Dopamine neurons play a central role in sustaining hedonic eating

A previously overlooked dopamine-producing brain circuit drives hedonic eating, or eating for pleasure, according to a new study in mice.

27 Mar 2025

Semaglutide

Overview

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Latest Semaglutide News and Research

What’s behind Gen Z’s skepticism about Ozempic and Wegovy

Body image concerns drive interest in GLP-1 weight loss drugs, study finds

Monell study offers renewed hope for people living with Bardet-Biedl Syndrome

Study: Women show greater awareness of obesity drugs than men

GLP1 agonists linked to depression risk in new genetic study

New Canadian guidelines offer comprehensive approach to managing pediatric obesity

Comparing single cell RNA methods to improve gastrointestinal cancer research

New findings highlight a shifting landscape for weight loss and glucose managing medications

GLP-1 agonists may reshape the gut microbiome

Study shows minimal lean muscle mass loss with GLP-1 and GLP-1/GIP therapy for weight loss

Semaglutide linked to higher risk of vision problems, FDA data analysis shows

American College of Physicians announces $260,000 in grants to advance equitable obesity care

Experts develop new guidelines for the treatment of schizophrenia

Rare sugars curb appetite and mimic diabetes drugs in mice

UVA Health experts highlight a growing array of treatment options for type 2 diabetes

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

Why sucralose could make you hungrier instead of helping you lose weight

Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes

Dopamine neurons play a central role in sustaining hedonic eating

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Semaglutide

Overview

Latest Semaglutide News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in